At the conclusion of the evaluation Merial has the first option to enter into a license agreement with Global Green for the manufacture distribution and sale of the vaccine. Details of the evaluation agreement are confidential.

Salmogenics is the only patented salmonella vaccine injected into the egg before the chick is hatched.

Salmogenics significantly reduces the presence of salmonella in the chicken. Salmonella is an anaerobic bacteria that may enter the digestive tract of humans and other mammals in contaminated food and cause abdominal cramps and pain violent vomiting and diarrhea or severe dehydration;it can also enter the bloodstream which may lead to death.

The aim of the Salmogenics vaccine is to improve the immune system health and welfare of the 40 billion broiler chickens in the world and to provide a healthier source of protein for humans in a more cost-effective manner.

Salmogenics testing has demonstrated a stronger immune system against salmonella as well as increased weight gain and reduced mortality in poultry. Salmogenics could lessen the need for use of antibiotics an essential benefit to both the poultry industry and ultimately consumers.

Dr Mehran Ghazvini DC NMD Chairman and CEO of Global Green Inc. said: “This agreement with a world leader in the animal health sector such as Merial further confirms the significance of our patented Salmogenics vaccine technology.

"Our goal at Global Green Inc. is to produce vaccines that improve early immunity in chickens and other animals providing a safer and more cost-effective food source. Global Green Inc.’s approach to animal health is to produce innovative environmentally-safe products and solutions which enhance the health well-being and performance of animals.”